ProCure Proton Therapy Center Highlights PSA Testing Nuances Amid Prostate Cancer Awareness Month
Event summary
- ProCure Proton Therapy Center marked National Prostate Cancer Awareness Month with a case study from Dr. Edward Soffen, highlighting that a 'normal' PSA level (under 4 ng/mL) can still indicate prostate cancer.
- Dr. Soffen's diagnosis was confirmed through a urine DNA test, MRI, and biopsy after his PSA level fluctuated despite being within the normal range.
- Dr. Soffen chose proton therapy over other radiation treatments due to its precision in targeting tumors while sparing surrounding tissue.
- ProCure has treated over 8,000 patients, including 750+ pediatric cases, since opening in March 2012.
The big picture
ProCure's emphasis on the limitations of PSA testing aligns with broader industry trends toward more comprehensive diagnostic approaches in oncology. The case study underscores the strategic importance of proton therapy in ProCure's portfolio, particularly as a non-surgical option with fewer side effects. With over 8,000 patients treated, ProCure is positioning itself as a key player in advanced radiation therapy, competing with other specialized cancer treatment centers.
What we're watching
- Diagnostic Advancements
- How the integration of urine DNA tests and MRIs with PSA testing will affect early prostate cancer detection rates.
- Treatment Preference
- Whether ProCure can capitalize on the growing preference for proton therapy among patients seeking non-surgical options.
- Market Expansion
- The pace at which ProCure can expand its patient base beyond the tri-state region, particularly for pediatric cases.